The p160 steroid receptor coactivators (SRCs) SRC-1, SRC-2 [nuclear receptor coactivator (NCOA)2], and SRC-3 [amplified in breast cancer 1 (AIB1)/NCOA3] are key pleiotropic "master regulators" of transcription factor activity necessary for cancer cell proliferation, survival, metabolism, and metastasis. SRC overexpression and overactivation occur in numerous human cancers and are associated with poor clinical outcomes and resistance to therapy. In prostate cancer (PC), the p160 SRCs play critical roles in androgen receptor transcriptional activity, cell proliferation, and resistance to androgen deprivation therapy. We recently demonstrated that the E3 ubiquitin ligase adaptor speckle-type poxvirus and zinc finger (POZ) domain protein (SPOP) interacts directly with SRC-3 and promotes its cullin 3-dependent ubiquitination and proteolysis in breast cancer, thus functioning as a potential tumor suppressor. Interestingly, somatic heterozygous missense mutations in the SPOP substrate-binding cleft recently were identified in up to 15% of human PCs (making SPOP the gene most commonly affected by nonsynonymous point mutations in PC), but their contribution to PC pathophysiology remains unknown. We now report that PC-associated SPOP mutants cannot interact with SRC-3 protein or promote its ubiquitination and degradation. Our data suggest that wild-type SPOP plays a critical tumor suppressor role in PC cells, promoting the turnover of SRC-3 protein and suppressing androgen receptor transcriptional activity. This tumor suppressor effect is abrogated by the PC-associated SPOP mutations. These studies provide a possible explanation for the role of SPOP mutations in PC, and highlight the potential of SRC-3 as a therapeutic target in PC.
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proteasome | MATH domain | BTB domain P rostate adenocarcinoma (PC) arises as an androgen-sensitive, androgen receptor (AR)-dependent malignancy, as highlighted by the clinical anticancer activity of gonadal androgen suppression and of recently approved agents such as the androgen synthesis inhibitor abiraterone (1) and the AR antagonist enzalutamide (2) . The importance of the AR axis in PC pathophysiology is further illustrated by the frequent overexpression in PC, especially after exposure to androgen deprivation therapy, of enzymes involved in androgen synthesis (3) , as well as AR itself (3) and AR coactivators (4, 5) .
The p160 steroid receptor coactivators (SRCs) SRC-1, SRC-2 (also known as TIF2, GRIP1, and NCOA2), and SRC-3 (also known as AIB1, ACTR, and NCOA3) are key pleiotropic "master regulators" of transcription factor activity necessary for cancer cell proliferation, survival, metabolism, and metastasis (6) . SRC overexpression and overactivation occur in numerous human cancers due to a variety of genomic, transcriptional, and posttranslational mechanisms, and are associated with poor clinical outcomes and resistance to therapy, suggesting that the SRCs are important therapeutic targets (6) . In PC, the p160 SRCs play critical roles in AR transcriptional activity, cell proliferation, migration, and resistance to androgen deprivation therapy (7) (8) (9) . Depletion of p160 SRCs in hormone-dependent PC and in CRPC cell lines impedes cell proliferation and AR transcriptional activity, including that of the AR-dependent induction of TMPRSS2-ERG (4, 6, (10) (11) (12) (13) . Elevated expression of all three p160 SRCs occurs in PC and is associated with a shorter time to recurrence and overall more aggressive disease (4, 12) . Gene amplification, point mutations, and widespread overexpression of SRC-2 (NCOA2) have been reported in PC and are associated with increased AR transcriptional activity and inferior clinical outcomes (5) .
However, the mechanisms underlying the overexpression of SRC-3 protein in PC are less well defined, especially as SRC-3 gene amplifications or mRNA overexpression are not commonly encountered in PC (5, 14, 15) . Instead, it is possible that SRC-3 expression could be regulated posttranslationally.
We recently demonstrated that the E3 ubiquitin ligase adaptor speckle-type POZ protein (SPOP) interacts directly with SRC-3 and promotes its cullin 3 (Cul3)-dependent ubiquitination and proteolysis in breast cancer, thus functioning as a potential tumor suppressor (16) . SPOP contains two conserved domains: an N-terminal MATH (Meprin and Traf Homology) domain that recruits substrate proteins, and a C-terminal BTB (Bric-a-bracTramtrack-Broad complex) domain that interacts with Cul3 (17, 18) . Somatic heterozygous missense SPOP mutations, clustered in the MATH domain (Fig. 1A) , were recently identified in 6-15% of PCs (19) (20) (21) , but their contribution to PC pathophysiology remains unknown.
In the present study, we wished to determine the impact of wildtype (WT) and mutant (mt) SPOP on SRC-3 protein turnover and AR transcriptional activity. Our data suggest that SPOP WT plays a critical tumor suppressor role in PC cells by promoting the turnover of SRC-3 protein and, thus, suppressing AR transcriptional activity. This tumor suppressor effect is abrogated by the PC-associated SPOP mutations. These studies provide a possible explanation for the role of SPOP mutations in PC, and highlight the potential of SRC-3 as a therapeutic target in PC.
Results

PC-Associated SPOP Mutants Lack the Capacity of SPOP
WT to Interact with SRC-3. Because the PC-associated SPOP mutations cluster in the substrate-binding MATH domain (Fig. 1A) , we hypothesized that they interfere with the capacity of SPOP to recruit SRC-3. Using coimmunoprecipitation (co-IP) in transiently transfected HEK293T cells, we confirmed that SPOP WT can be immunoprecipitated together with FLAG-tagged SRC-3 (Fig. 1B) , but not SRC-1 or SRC-2 (Fig. S1A) . The interaction between SPOP and SRC-3 was attenuated in the case of the PC-associated SPOP mutants (Fig. 1B) .
WT to Promote SRC-3 Protein Turnover. We next examined the capacity of PCassociated SPOP mutants to promote degradation of SRC-3 protein.
In agreement with our previous report (16) , exogenous expression of SPOP WT in HEK293T cells efficiently promoted degradation of SRC-3 protein in a dose-dependent manner ( Fig. 2A) . Furthermore, we also documented that this action of SPOP is unique to SRC-3, as SPOP WT did not promote degradation of the other two p160 SRC family members, SRC-1 or SRC-2 (Fig. S1B) . However, none of the PC-associated SPOP mutants could promote degradation of SRC-3 protein ( Fig. 2A) . Whereas certain SPOP mutants induced no change in SRC-3 protein levels (loss-of-function effect), other SPOP mutants (such as F102C, F125V, and W131G) increased SRC-3 protein levels above baseline (i.e., no exogenous SPOP) levels, suggesting a possible gain-of-function "dominantnegative effect."
Reverse transcription-quantitative real-time PCR (RT-qPCR) analysis demonstrated that SRC-3 mRNA levels were not affected by any SPOP (WT or mutant), which confirmed our prior finding that the impact of SPOP WT on SRC-3 expression is posttranslational (16 293T cells were transiently transfected with 3 μg His-Ub and 5 μg FLAG-SRC-3, together with 10 μg FLAG-HA-tagged wild-type SPOP or HA-tagged SPOP mutants [PC-associated mutants or SPOP(ΔBTB)] for 48 h, and then treated with proteasome inhibitor (20 μM MG132 for 2 h). Cells were harvested under denaturing conditions. His-Ub-modified cellular proteins were purified by Ni-NTA agarose resin and subjected to SDS/PAGE. Ubiquitinated SRC-3 was detected by immunoblotting with anti-SRC-3 antibody (topmost panel). Cell extracts were also probed with antibodies against FLAG for F-SRC-3, HA for wild-type or SPOP mutants, or tubulin (loading control). SPOP WT , but Not Its PC-Associated Mutants, Promotes Ubiquitination of SRC-3 Protein Through a Mechanism That Requires the SPOP BTB Domain. We have previously reported that deletion of the 203 carboxyl-terminal amino acid residues from SPOP (amino acids 172-374, a region that includes amino acids 184-297, the BTB domain; Fig. 1A ) abrogates its capacity to bind cullin 3 and promote degradation of SRC-3 (16) . We now generated an expression vector encoding SPOP that lacks only amino acids 184-297, the BTB domain [SPOP(ΔBTB)]. As a result, SPOP(ΔBTB) cannot bind cullin 3. We found that, although SPOP(ΔBTB) retains the capacity to bind SRC-3 (Fig. 2B) , it cannot promote degradation of SRC-3 in prostate cancer PC-3 cells (Fig. 2C) . For comparison, the PC-associated SPOP F133V cannot bind SRC-3 ( Fig. 2B ) and cannot promote its degradation (Fig. 2C) .
These data suggest that SPOP-mediated degradation of SRC-3 requires the BTB domain-mediated recruitment to cullin 3 (which is necessary for substrate ubiquitination). Indeed, in agreement with our prior report (16), we confirmed that SPOP WT promotes SRC-3 ubiquitination (Fig. 2D) . However, PC-associated SPOP mutants and SPOP(ΔBTB) also failed to promote SRC-3 ubiquitination (Fig. 2D) , thus providing an explanation for their inability to promote SRC-3 degradation. Of note, a subset of SPOP mutants decreased SRC-3 ubiquitination below baseline (i.e., no exogenous SPOP) levels, again suggesting a possible dominant-negative effect of these SPOP mutants on the function of endogenous (WT) SPOP.
WT to Attenuate the Coactivator Function of SRC-3 on AR Transcriptional Activity. Because SRC-3 is an important coactivator of the transcriptional activity of AR, we next examined the impact of these PC-associated SPOP mutants on AR activity in vitro. First, we transiently expressed SPOP WT or SPOP mutants in HepG2 cells and quantified their capacity to modulate the impact of SRC-3 on AR transcriptional activity, using a reporter plasmid carrying a 6-kb fragment of the promoter/enhancer region of the prostate-specific antigen (PSA; gene name: kallikrein-related peptidase 3; KLK3) gene. This region harbors three functionally active AR-binding sites (androgen response elements; AREs) (22) . As anticipated, we found that SRC-3 can robustly stimulate the transcriptional response of the KLK3 gene promoter/enhancer to androgen. This effect is significantly attenuated by SPOP WT , but not by the PC-associated SPOP mutants (Fig. 3) . Once again, a subset of mutants (including F102C, F125V, and W131G) increased AR transcriptional activity above baseline (i.e., no exogenous SPOP) levels, suggesting a possible gain-of-function dominant-negative effect of these SPOP mutants on the function of endogenous (WT) SPOP. (Fig. 4A) . Induction of SPOP WT with doxycycline potently suppressed endogenous SRC-3 protein levels. On the contrary, this suppressive effect was not seen upon induction of SPOP mutants by doxycycline (Fig. 4B) . (Fig. 5A) . Similar results were seen (Fig. S2) for the expression of IGF1 [a gene known to be SRC-3-dependent in PC cells (8) ] and FKBP5 (also known to be AR-dependent in PC cells). Finally, using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, we examined the impact of doxycyclineinduced WT and mutant SPOPs on the proliferative rate of LNCaP-Abl PC cells. We documented a tumor suppressor effect for SPOP WT in LNCaP-Abl PC cells, which was attenuated in the case of mutant SPOPs (Fig. 5B) .
Endogenous SPOP Regulates SRC-3 Protein Expression and Suppresses AR Transcriptional Activity in PC Cells. Finally, we explored whether endogenous SPOP regulates SRC-3 expression and AR transcriptional activity in a panel of six commonly used AR-positive PC cell lines (three androgen-dependent and three androgenindependent). All six cell lines had been previously found, by Sanger sequencing, to lack mutations in the SPOP-coding sequence. We found that silencing SPOP via siRNA resulted in increased SRC-3 protein levels and increased expression of the AR-target gene PSA (KLK3; Fig. S3 ). These data confirm that SPOP is an endogenous regulator of SRC-3 protein turnover and AR activity in PC cells and provide a possible explanation for the fact that it is the most commonly mutated gene in PC.
Discussion
Recent exome-sequencing studies have identified SPOP as the gene most commonly affected by somatic nonsynonymous point mutations in PC (19) (20) (21) . However, the role of these SPOP mutants in PC pathophysiology was unknown. We have previously characterized a Cul3-based, SPOP-dependent complex as an E3 ubiquitin ligase that promotes ubiquitination and posttranslational turnover of SRC-3 protein (16). As SRC-3 can potently promote AR transcriptional activity and pleiotropic oncogenic signaling necessary for cancer cell proliferation, survival, metabolism, and metastasis, we hypothesized that SRC-3 could be one of the major SPOP substrates mediating the effect of mtSPOP in PC and investigated the impact of WT and mtSPOP on SRC expression and function. Overexpression of SPOP WT potently promoted the degradation of SRC-3 protein, but not SRC-1 or SRC-2 protein. All PC-associated SPOP mutants tested failed to promote SRC-3 ubiquitination and protein degradation. We further documented the physical interaction of SPOP WT with SRC-3 (but not SRC-1 or SRC-2), and this interaction was abolished in these PC-associated SPOP mutants. In PC cells, SPOP WT suppresses SRC-3 protein expression, cell proliferation, and AR transcriptional activity, whereas this effect is abolished or significantly attenuated by the PC-associated SPOP mutations.
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We have previously reported that the SPOP N-terminal MATHcontaining domain directly binds to SRC-3, whereas the SPOP C-terminal BTB-containing domain directly binds to Cul3 (16) . A five-residue φ-π-S-S/T-S/T (φ, nonpolar; π, polar) SPOP-binding consensus motif has been described (18) , and a similar sequence is present in SRC-3 upon phosphorylation of SRC-3 at S102 (16) . This site is phosphorylated by casein kinase Ie (16) . Therefore, SPOP can act as an adaptor for this Cul3-based ubiquitin ligase complex and target the SRC-3 protein for degradation in a phosphorylation-dependent manner (16) . We now demonstrate that this effect is restricted to SRC-3, and not present in SRC-1 or SRC-2. Importantly, this tumor suppressor effect of SPOP is abolished or significantly attenuated by the human PC-associated SPOP mutations that cluster in the MATH domain. These data highlight SRC-3 as an effector of the SPOP mutations in PC.
SRC-3 (AIB1/ACTR/NCOA3) is a key pleiotropic master regulator of transcription factor activity necessary for cancer cell proliferation, survival, metabolism, and metastasis. SRC-3 overexpression and overactivation occur in numerous human cancers, due to a variety of genomic, transcriptional, and posttranslational mechanisms, and are associated with poor clinical outcomes and resistance to therapy. Not surprisingly, SRC-3 protein turnover is controlled at multiple levels. Inactive, steady-state SRC-3 can be degraded in a ubiquitin-and ATP-independent manner by the REGγ proteasome (23) . When activated by phosphorylation at a number of important sites (including the essential SRC-3 phosphodegron residues S101 and S102), SRC-3 stability is mainly controlled by the SPOP-Cul3-Rbx1 ubiquitin ligase complex, in a mechanism regulated by the balance between phosphorylation at S102 [e.g., by casein kinase Ie (16) degradation (25) . This highly complex network of three posttranslational modification mechanisms that control the stability and function of SRC-3 highlights its importance as a potent master regulator of gene expression.
Of note, our experimental results have raised the possibility that certain SPOP mutants (including F102C and W131G) may exert a "gain-of-function" oncogenic effect by increasing SRC-3 protein levels and AR transcriptional activity above baseline (i.e., no exogenous SPOP) levels. This phenomenon, which could be attributed to a putative dominant-negative effect on the function of SPOP WT , may acquire particular importance because SPOP mutations are heterozygous in prostate cancer specimens. However, it should be acknowledged that there was some variability in the behavior of these SPOP mutants across our wide spectrum of experimental models and readouts; that is, the same SPOP mutant did not always behave as a dominant-negative across all models and assays (although all SPOP mutants were consistently and universally found to have attenuated tumor suppressor properties compared with SPOP WT ). Such variability is perhaps attributable to underlying variation in our model systems or other experimental conditions. As a result, the identification and delineation of a unifying model for the dominant-negative function of these SPOP mutants will require additional detailed studies. In any case, our data hint at possible functional differences between the various SPOP mutants regarding their oncogenic potential and even prognostic significance, which, obviously, will need to be validated in clinically annotated human prostate cancer specimens.
Obviously, SPOP is known to bind and promote the ubiquitination of other substrates, including the death domain-associated protein Daxx (26) , the phosphatase Puc, the transcriptional regulator Ci/Gli (27) , the variant histone MacroH2A (18) , and several others. Therefore, SPOP mutations could possibly affect other signaling pathways beyond SRC-3/AR, and our data do not exclude such a hypothesis. However, we have provided strong evidence that the transcriptional coactivator SRC-3 and the nuclear hormone receptor AR, both critically important for PC pathophysiology and resistance to therapy, are downstream effectors of SPOP. As the PC-associated SPOP mutations are predicted to be loss-of-function, they may not be directly druggable for therapeutic purposes. A targeted-treatment approach to SPOP mutations in PC could be to inhibit its downstream substrates that accumulate in the absence of SPOP function. Our study identifies SRC-3 as a mediator of the oncogenic effects of mtSPOP and highlights the need to develop inhibitors of the p160 SRCs.
In summary, we have demonstrated that SPOP WT plays a critical tumor suppressor role in PC cells by promoting the ubiquitination and proteasomal degradation of SRC-3 protein and, thus, suppressing AR transcriptional activity. This tumor suppressor effect is abrogated by the PC-associated SPOP mutations. Our data provide a possible explanation for the impact of the recurrent somatic heterozygous missense mutations in the SPOP MATH domain that were recently identified in a subset of human PCs (19) (20) (21) , and highlight again the potential of SRC-3 as a therapeutic target in PC.
Materials and Methods
Cell Culture. Human embryonic kidney 293T cells (American Type Culture Collection) were cultured in DMEM high-glucose (Invitrogen) with 10% (vol/ vol) FBS (Invitrogen) in a 5% (vol/vol) CO 2 incubator at 37°C. LNCaP-Abl cells, a PC cell line derived from LNCaP cells via selection in androgen-depleted medium (supplemented with 10% charcoal-stripped FBS; CSS) (28) , was a generous gift from Zoran Culig (University of Innsbruck, Innsbruck, Austria) and maintained in RPMI1640 (Invitrogen) supplemented with 10% CSS. Doxycycline-inducible Abl stable transfectants were maintained in RPMI1640 supplemented with 10% tetracycline-free FBS (Atlanta Biologicals, Inc.) and 300 μg/mL of the selection antibiotic G-418 (Invitrogen). Human hepatoblastoma HepG2 cells (American Type Culture Collection) were maintained in 5% CO 2 at 37°C in Eagle's MEM (Invitrogen) with 10% FBS (Invitrogen).
Expression Constructs. Using Phusion High-Fidelity DNA Polymerase (New England BioLabs) and PCR primers containing an HA tag at the N terminus, an expression construct of HA-tagged SPOP (pcDNA3.1-HA-SPOP, wild-type) was constructed by insertion of the PCR-amplified SPOP cDNA-coding sequence into mammalian expression vector pcDNA3.1 Hygro (+) (Invitrogen). In vitro site-directed mutagenesis was used to obtain the HA-tagged SPOP mutants by two PCR amplifications using pcDNA3.1-HA-SPOP as the template. The PCR-amplified DNAs coding for mutated SPOPs were inserted into pcDNA3.1 Hygro (+) (Invitrogen) to generate the corresponding mammalian expression vectors: pcDNA3.1-HA-SPOP Reverse Transcription-Quantitative Real-Time PCR. Reverse transcription and PCR reactions were performed with a TaqMan RNA-to-CT 1-Step Kit (Applied Biosystems) using a StepOnePlus Real-Time PCR System (Applied Biosystems). Results were normalized to the same amount of total RNA. The primers and probes used for KLK3, IGF1, SRC-3, and FKBP5 transcripts are listed in Table S2 .
Reporter Assay Analysis. Human hepatoblastoma HepG2 cells (American Type Culture Collection) were maintained in 5% CO 2 at 37°C in Eagle's MEM (Invitrogen). Cells were plated at 1 × 10 5 cells per well in 24-well tissue culture plates and transfected with 3 ng of pCMV5-AR, 100 ng of the PSA61-luc reporter vector [that carries a 6-kb fragment of the PSA promoter/enhancer region, harboring three functional AREs, inserted upstream of the reporter gene (22) ], 100 ng of pCR3.1-SRC-3 (or empty vector), and 100 ng of pcDNA3.1 plasmids encoding WT SPOP or each mutant SPOP (or empty vector), using Lipofectamine LTX and Plus Transfection Reagent (Invitrogen). Twenty-four hours after transfection, synthetic androgen (R1881) or vehicle was added to the appropriate wells (final concentration of R1881, 10 nM). Luciferase activity was determined 24 h later using the Promega Luciferase Assay Kit according to the manufacturer's protocols.
In Vivo Ubiquitination Assay. For analysis of the ubiquitination of SRC-3 in cells, 293T cells were transiently cotransfected with His-Ub, FLAG-tagged SRC-3, and either FLAG-HA-tagged wild-type SPOP or HA-tagged SPOP mutants. Fortyeight hours posttransfection, cells were treated with 20 μM MG132 for 2 h and harvested under denaturing conditions, as described (33) . His-Ub-conjugated cellular proteins were purified by Ni-NTA agarose resin. Ubiquitinated SRC-3 was detected using SDS/PAGE and immunoblotting with the anti-SRC-3 antibody.
MTT Assay. Cells were plated in 24-well plates in medium containing 10% FBS and allowed to adhere for 24 h. Then, drugs were added, and the cells were incubated for 96 more hours. Cell numbers were quantified by MTT (SigmaAldrich) as previously described (31, 32) , and expressed as a percentage of the value of control wells. All experiments were repeated at least three times, with each experimental condition repeated at least in quadruplicate per experiment.
Statistical Analysis. Each experiment was repeated at least three times. Fold changes in mRNA levels (RT-qPCR), reporter assay activity, or cell number (absorbance in MTT assay) were compared between differently treated samples (with or without doxycycline treatment) using one-way ANOVA. In all analyses, P < 0.05 was considered statistically significant.
